NCT03275285: A reported trial by Sanofi
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03275285 |
|---|---|
| Title | Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 25, 2017 |
| Completion date | Jan. 14, 2022 |
| Required reporting date | Jan. 14, 2023, midnight |
| Actual reporting date | Jan. 13, 2023 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |